Long-term follow-up studies on healthy volunteer peripheral blood stem cell (PBSC) donors who receive granulocyte colony-stimulating factor (G-CSF) are not yet available. Nagler et al. 1 recently published a report which concluded that the use of G-CSF in healthy stem cell donors led to 'cancer-characteristic DNA modifications'. In this study, they tested 41 peripheral blood samples obtained from 18 healthy stem cell donors (13 males and five females, age range 11-50 years) given G-CSF to mobilize stem cells. Eighteen samples were obtained during mobilization and collection and 23 were taken at time intervals ranging from 8 to 268 days following mobilization. The authors performed fluorescence in situ hybridization (FISH) studies and reported a loss of synchrony in allelic replication timing and the occurrence of aneuploidy. Loss of allelic replication synchrony was found in the lymphocytes from G-CSF-mobilized donors, but was a transient epigenetic modification. The occurrence of aneuploidy remained unchanged and was thought to have occurred via changes in DNA methylation capacity. 1 These findings might have implications for the continued administration of G-CSF to PBSC donors.
By contrast, Hernandez et al. 2 studied gene expression profiles using microarray technology in peripheral blood samples from nine healthy donors who received G-CSF. Samples were collected before G-CSF administration and in three donors at 2 and 6 months post-mobilization. Three hundred and seventy-four genes showed a transient increase in expression and 387 a decrease in expression, but not when the pre-G-CSF samples were compared with those taken 2 or 6 months later. The expression of a number of genes, for example, CD11b, intracellular adhesion molecule (ICAM)-2 and those involved in the immune response showed expected changes in expression. They concluded that their results accorded with clinical studies showing no significant side effects in healthy donors mobilized with G-CSF. They stated that G-CSF appears to be safe for healthy volunteer donors of haemopoietic stem cells. 2 The Joint UK Bone Marrow Donor Registries Medical Advisory Committee has considered the implications of these findings and consulted others in the field for their views. It is likely that the levels of G-CSF obtained during priming are probably higher than seen under any physiological circumstances such as infection, so unexpected effects cannot be ruled out from first principles. However, colleagues at the University of Minnesota followed up volunteer donors who received G-CSF for 1 year with routine haematology evaluations and found no long-term abnormalities. 3 It is difficult to plan long-term studies with the aim of comparing the incidence of leukaemia between healthy people who receive G-CSF and those who do not since the latency period is about 8 years. Moreover, the annual incidence of leukaemia in the general population is one in 10 000 and if one were to assume that G-CSF would increase the incidence 10-fold (10 in 10 000), it would be necessary to follow 2000 normal recipients of G-CSF for 10 years to see a significant increase in leukaemia from the background incidence. 4 Data from the Severe Congenital Neutropenia (SCN) Registry shows an incidence of acute myeloid leukaemia (AML) and myelodysplasia syndrome (MDS) of 9% (31/352) in 352 SCN patients treated with G-CSF and observed for a mean of 6 years, which is consistent with a constitutional predisposition to develop malignant change, whereas none of 344 patients with cyclic or idiopathic neutropenia treated with G-CSF, who presumably have no such predisposition, developed MDS or AML. 5 The US National Marrow Donor Program (NMDP) has discussed the findings with their Institutional Review Board and Donor Protection and Safety Monitoring committees and has agreed not to change their policy on G-CSF administration at the present time. The NMDP has not seen any cases of leukaemia in PBSC donors, so the magnitude of the laboratory effects observed do not correlate with the clinical findings. They believe that it is premature to change policy based on this report and plan to conduct a molecular study in conjunction with the University of Minnesota, aiming to investigate 20 G-CSFmobilized donors and 20 controls with follow-up samples over a 1-year period.
Nagler et al. 1 observed genetic aberrations in the Tlymphocytes of healthy donors using interphase cell singlecolour FISH analysis (iFISH) with centromere probes. Unfortunately, values of 7% or less of cells positive for aneuploidy, as shown in control samples, are well below the rates of false-positive results for the iFISH probes used. We believe that further studies are therefore warranted to confirm or refute the findings of Nagler and colleagues. The UK Registries therefore propose to screen for long-term/ permanent genetic damage comparing G-CSF-mobilized PBSC donors with marrow donors (negative controls) and patients with haematological malignancies (positive controls) using interphase FISH and array comparative genomic hybridization analysis. These methods will be used to screen cell preparations and DNA extractions made from phytohaemagglutinin-stimulated peripheral blood lymphocyte cultures. In addition, we continue to collect and collate follow-up data on the general health and blood counts of all UK volunteer donors who receive G-CSF. 
